▶ 調査レポート

免疫オンコロジーの世界市場

• 英文タイトル:Global Market Study on Immuno-Oncology: Immune Checkpoint Inhibitors Segment Projected to be the Most Lucrative Segment by Therapy Type

Persistence Market Researchが調査・発行した産業分析レポートです。免疫オンコロジーの世界市場 / Global Market Study on Immuno-Oncology: Immune Checkpoint Inhibitors Segment Projected to be the Most Lucrative Segment by Therapy Type / B-PMR-393資料のイメージです。• レポートコード:B-PMR-393
• 出版社/出版日:Persistence Market Research / 2017年4月19日
• レポート形態:英文、PDF、184ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・バイオ
• 販売価格(消費税別)
  Individual(1名、印刷不可)¥524,300 (USD4,900)▷ お問い合わせ
  Multi User(5名)¥813,200 (USD7,600)▷ お問い合わせ
  Corporate User¥1,134,200 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートでは、免疫オンコロジーの世界市場について調査・分析し、関連企業情報、産業分析、免疫オンコロジーの世界市場規模、市場動向、セグメント別市場分析、地域別市場規模(欧州、アメリカ、アジアなど)、市場予測データを含め、以下の構成でお届けいたします。

Persistence Market Research presents a comprehensive analysis of the global immuno-oncology market in a new publication titled “Immuno-Oncology Market: Global Industry Analysis and Forecast 2017-2025.” This report covers the analysis of immunotherapy-based products being used for different cancer indications across different geographical regions over an eight year forecast period 2017 – 2025, which provides useful insights highlighting the various opportunities available to market investors, drug manufacturers, healthcare professionals and other key stakeholders operating in the global immuno-oncology market. In the process of analyzing the global immuno-oncology market, extensive research has gone into identifying the various therapies used in the treatment of cancers that form the core components of the scope of study, as well as highlighting numerous developments that are likely to impact the global immuno-oncology market performance during the period of assessment. A dedicated effort has gone into classifying the various market drivers and restraints, trends, and opportunities for players operating in the global immuno-oncology market in the coming years. Through extensive research, a dedicated team of healthcare analysts at Persistence Market Research have studied how the different market dynamics are likely to impact the current environment and future scenario of the global immuno-oncology market, thereby providing useful insights to market players to plan their differentiating strategies capable of evolving with the changing market landscape.
Report Structure

The publication on the global immuno-oncology market begins with a crisp executive summary that highlights the current market scenario, key market dynamics and a forecast of the global immuno-oncology market revenue during 2017 – 2025. This is followed by important market definitions and the market taxonomy, highlighting the various categories covered in the scope of the report. A snippet of key developments in the global immuno-oncology market has been provided, followed by cancer epidemiology data for key regions covered in the report. The next section provides a deep dive into the key market dynamics and presents qualitative insights into the various drivers, challenges, and market trends that are likely to define the global immuno-oncology market in the next few years. The report then jumps into a comprehensive analysis of the global immuno-oncology market in terms of revenue, including Y-o-Y growth projections and absolute dollar opportunity analysis, highlighting key takeaways and performance metrics.

The last section of the report is devoted to showcase the market performance of some of the key players operating in the global immuno-oncology market. The report profiles a few of the leading manufacturers of immunotherapies and presents a detailed analysis of their overall business performance and a comprehensive evaluation of product and business strategies, highlighting some of the recent developments for each player in this market. This section is intended to provide report audiences with a dashboard view of the competitive landscape of the global immuno-oncology market, as well as the market share held by some of the major players operating in this market.

Global Immuno-Oncology Market Segmentation

By Therapy Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others (immune cell therapy, etc.)
By Therapeutic Area
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers (head and neck cancer, etc.)
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Region
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Research Methodology

Exhaustive primary and secondary research forms the core of Persistence Market Research’s tested research methodology for forecasting the global immuno-oncology market performance over the assessed period. Data thus acquired is sliced and diced based on the relevant parameters and further validated using the triangulation method and finally scrutinized using advanced tools to glean pertinent qualitative and quantitative insights into the global immuno-oncology market. All the insights provided in this report are supported by relevant metrics estimated for the various market segments across the assessed regions. The report is a comprehensive bundle of useful market insights and critical data points pertaining to the global immuno-oncology market and is intended to provide readers with a magnified view of the global immuno-oncology market over the next eight years.

Market Sizing and Forecasting

When developing the market forecast, the first step is to size the current market, which forms the basis for forecasting how the global immuno-oncology market is anticipated to perform in the future. The analysts have used a bottom-up approach to assess market numbers for each therapy category and counter-validated market estimations by analyzing spending on oncology treatments globally. Also, macro-economic indicators such as healthcare expenditure, epidemiology of cancer, adoption of different types of therapies and a comprehensive assessment of drugs in the pipeline have been considered to forecast market numbers.

Key Metrics

This report on the global immuno-oncology market encapsulates the key metrics that accurately describe the growth trajectory of the global immuno-oncology market over the next eight years. The analysts have used this data to compare market performance across the various segments and regions. Besides estimating the Compound Annual Growth Rate (CAGR) for the global and regional markets, the report also presents an in-depth analysis of the global immuno-oncology market on the basis of parameters such as Year-on-Year (Y-o-Y) growth to understand market predictability and to identify the right opportunities likely to emerge in the global immuno-oncology market.

Further, the different market segments have been studied by performing a Basis Point Share (BPS) analysis to understand the relative contribution of individual segments to overall market growth. Another notable feature of this report is an analysis of the revenue forecast of the global immuno-oncology market in terms of absolute dollar opportunity. While this is usually overlooked when forecasting the market, absolute dollar opportunity analysis is critical in assessing the level of opportunity that market players can look to achieve and also to identify potential resources in the global immuno-oncology market. Finally, the importance of dissecting the different market segments in terms of their growth and performance in the global immuno-oncology market cannot be stressed enough; and towards this end, Persistence Market Research has developed a unique market attractiveness index to help market players identify current and future market opportunities.

レポート目次

1. Executive Summary

2. Immuno-Oncology Market Introduction
2.1. Market Introduction and Definitions
2.2. Market Taxonomy

3. Global Immuno-Oncology Market Analysis Scenario
3.1. Market Scenario (US$ Mn) Forecast
3.2. Market Size (US$ Mn) and Forecast
3.2.1. Market Value (US$ Mn) and Y-o-Y Growth
3.2.2. Absolute $ Opportunity
3.3. Key Market Developments
3.4. Cancer Epidemiology, by Region
3.5. Regulatory Scenario
3.6. Patient Support Programs
3.7. Pipeline Snapshot

4. Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Trends

5. Global Immuno-Oncology Market Analysis and Forecasts, By Therapy Type
5.1. Introduction
5.2. Basis Point Share (BPS) Analysis By Therapy Type
5.3. Y-o-Y Growth Projections By Therapy Type
5.4. Market Value Forecast By Therapy Type, 2017–2025
5.4.1. Immune Checkpoint Inhibitors
5.4.1.1. PD-1
5.4.1.2. PD-L1
5.4.1.3. CTLA-4
5.4.2. Immune System Modulators
5.4.3. Cancer Vaccines
5.4.4. Oncolytic Virus
5.4.5. Other Therapies
5.5. Market Attractiveness By Therapy Type

6. Global Immuno-Oncology Market Analysis and Forecasts, By Therapeutic Area
6.1. Introduction
6.2. Basis Point Share (BPS) Analysis By Therapeutic Area
6.3. Y-o-Y Growth Projections By Therapeutic Area
6.4. Market Value Forecast By Therapeutic Area, 2017–2025
6.4.1. Melanoma
6.4.2. Lung Cancer
6.4.3. Blood Cancers
6.4.4. Renal Cell Carcinoma
6.4.5. Prostate Cancer
6.4.6. Bladder Cancer
6.4.7. Other Cancers
6.5. Market Attractiveness By Therapeutic Area

7. Global Immuno-Oncology Market Analysis and Forecasts, By End User
7.1. Introduction
7.2. Basis Point Share (BPS) Analysis By End User
7.3. Y-o-Y Growth Projections By End User
7.4. Market Value Forecast By End User, 2017–2025
7.4.1. Hospitals
7.4.2. Clinics
7.4.3. Ambulatory Surgical Centers
7.5. Market Attractiveness By End User

8. Global Immuno-Oncology Market Analysis and Forecasts, By Region
8.1. Basis Point Share (BPS) Analysis By Region
8.2. Y-o-Y Growth Projections By Region
8.3. Market Value Forecast By Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa
8.4. Market Attractiveness By Region

9. North America Immuno-Oncology Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis By Country
9.1.2. Y-o-Y Growth Projections By Country
9.2. Market Value Forecast By Therapy Type, 2017–2025
9.2.1. Immune Checkpoint Inhibitors
9.2.1.1. PD-1
9.2.1.2. PD-L1
9.2.1.3. CTLA-4
9.2.2. Immune System Modulators
9.2.3. Cancer Vaccines
9.2.4. Oncolytic Virus
9.2.5. Other Therapies
9.3. Market Value Forecast By Therapeutic Area, 2017–2025
9.3.1. Melanoma
9.3.2. Lung Cancer
9.3.3. Blood Cancers
9.3.4. Renal Cell Carcinoma
9.3.5. Prostate Cancer
9.3.6. Bladder Cancer
9.3.7. Other Cancers
9.4. Market Value Forecast By End User, 2017–2025
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Ambulatory Surgical Centers
9.5. Market Value Forecast By Country, 2017–2025
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Therapy Type
9.6.2. By Therapeutic Area
9.6.3. By End User
9.6.4. By Country
9.7. Drivers and Restraints: Impact Analysis

10. Latin America Immuno-Oncology Market Analysis and Forecast
10.1.Introduction
10.1.1. Basis Point Share (BPS) Analysis By Country
10.1.2. Y-o-Y Growth Projections By Country
10.2.Market Value Forecast By Therapy Type, 2017–2025
10.2.1. Immune Checkpoint Inhibitors
10.2.1.1. PD-1
10.2.1.2. PD-L1
10.2.1.3. CTLA-4
10.2.2. Immune System Modulators
10.2.3. Cancer Vaccines
10.2.4. Oncolytic Virus
10.2.5. Other Therapies
10.3.Market Value Forecast By Therapeutic Area, 2017–2025
10.3.1. Melanoma
10.3.2. Lung Cancer
10.3.3. Blood Cancers
10.3.4. Renal Cell Carcinoma
10.3.5. Prostate Cancer
10.3.6. Bladder Cancer
10.3.7. Other Cancers
10.4.Market Value Forecast By End User, 2017–2025
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Ambulatory Surgical Centers
10.5.Market Value Forecast By Country, 2017–2025
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6.Market Attractiveness Analysis
10.6.1. By Therapy Type
10.6.2. By Therapeutic Area
10.6.3. By End User
10.6.4. By Country
10.7. Drivers and Restraints: Impact Analysis

11. Europe Immuno-Oncology Market Analysis and Forecast
11.1.Introduction
11.1.1. Basis Point Share (BPS) Analysis By Country
11.1.2. Y-o-Y Growth Projections By Country
11.2.Market Value Forecast By Therapy Type, 2017–2025
11.2.1. Immune Checkpoint Inhibitors
11.2.1.1. PD-1
11.2.1.2. PD-L1
11.2.1.3. CTLA-4
11.2.2. Immune System Modulators
11.2.3. Cancer Vaccines
11.2.4. Oncolytic Virus
11.2.5. Other Therapies
11.3.Market Value Forecast By Therapeutic Area, 2017–2025
11.3.1. Melanoma
11.3.2. Lung Cancer
11.3.3. Blood Cancers
11.3.4. Renal Cell Carcinoma
11.3.5. Prostate Cancer
11.3.6. Bladder Cancer
11.3.7. Other Cancers
11.4.Market Value Forecast By End User, 2017–2025
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Ambulatory Surgical Centers
11.5.Market Value Forecast By Country, 2017–2025
11.5.1. Germany
11.5.2. U.K.
11.5.3. Italy
11.5.4. France
11.5.5. Spain
11.5.6. Rest of Europe
11.6.Market Attractiveness Analysis
11.6.1. By Therapy Type
11.6.2. By Therapeutic Area
11.6.3. By End User
11.6.4. By Country
11.7. Drivers and Restraints: Impact Analysis

12. Asia Pacific Immuno-Oncology Market Analysis and Forecast
12.1.Introduction
12.1.1. Basis Point Share (BPS) Analysis By Country
12.1.2. Y-o-Y Growth Projections By Country
12.2.Market Value Forecast By Therapy Type, 2017–2025
12.2.1. Immune Checkpoint Inhibitors
12.2.1.1. PD-1
12.2.1.2. PD-L1
12.2.1.3. CTLA-4
12.2.2. Immune System Modulators
12.2.3. Cancer Vaccines
12.2.4. Oncolytic Virus
12.2.5. Other Therapies
12.3.Market Value Forecast By Therapeutic Area, 2017–2025
12.3.1. Melanoma
12.3.2. Lung Cancer
12.3.3. Blood Cancers
12.3.4. Renal Cell Carcinoma
12.3.5. Prostate Cancer
12.3.6. Bladder Cancer
12.3.7. Other Cancers
12.4.Market Value Forecast By End User, 2017–2025
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Ambulatory Surgical Centers
12.5.Market Value Forecast By Country, 2017–2025
12.5.1. Japan
12.5.2. South Korea
12.5.3. Australia & New Zealand
12.5.4. China
12.5.5. Rest of Asia Pacific
12.6.Market Attractiveness Analysis
12.6.1. By Therapy Type
12.6.2. By Therapeutic Area
12.6.3. By End User
12.6.4. By Country
12.7. Drivers and Restraints: Impact Analysis

13. Middle East and Africa Immuno-Oncology Market Analysis and Forecast
13.1.Introduction
13.1.1. Basis Point Share (BPS) Analysis By Country
13.1.2. Y-o-Y Growth Projections By Country
13.2.Market Value Forecast By Therapy Type, 2017–2025
13.2.1. Immune Checkpoint Inhibitors
13.2.1.1. PD-1
13.2.1.2. PD-L1
13.2.1.3. CTLA-4
13.2.2. Immune System Modulators
13.2.3. Cancer Vaccines
13.2.4. Oncolytic Virus
13.2.5. Other Therapies
13.3.Market Value Forecast By Therapeutic Area, 2017–2025
13.3.1. Melanoma
13.3.2. Lung Cancer
13.3.3. Blood Cancers
13.3.4. Renal Cell Carcinoma
13.3.5. Prostate Cancer
13.3.6. Bladder Cancer
13.3.7. Other Cancers
13.4.Market Value Forecast By End User, 2017–2025
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Ambulatory Surgical Centers
13.5.Market Value Forecast By Country, 2017–2025
13.5.1. South Africa
13.5.2. GCC Countries
13.5.3. Rest of Middle East & Africa
13.6.Market Attractiveness Analysis
13.6.1. By Therapy Type
13.6.2. By Therapeutic Area
13.6.3. By End User
13.6.4. By Country
13.7. Drivers and Restraints: Impact Analysis

14. Competition Landscape
14.1. Market Share Analysis By Company (2016)
14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
14.2.1. Amgen, Inc.
14.2.2. AstraZeneca Plc
14.2.3. Bristol-Myers Squibb Company
14.2.4. Dendreon Corporation
14.2.5. F. Hoffmann-La Roche
14.2.6. Merck & Co., Inc.
14.2.7. Novartis AG
14.2.8. Pfizer, Inc.
14.2.9. Sanofi

15. Assumptions and Acronyms Used

16. Research Methodology

List of Tables

Table 01 : Global Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapy Type, 2016–2025
Table 02 : Global Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapeutic Area, 2016–2025
Table 03 : Global Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2025
Table 04 : Global Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Region, 2016–2025
Table 05 : North America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapy Type, 2016–2025
Table 06 : North America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapeutic Area, 2016–2025
Table 07 : North America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2025
Table 08 : North America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Country, 2016–2025
Table 09 : Latin America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapy Type, 2016–2025
Table 10 : Latin America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapeutic Area, 2016–2025
Table 11 : Latin America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2025
Table 12 : Latin America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Country, 2016–2025
Table 13 : Europe Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapy Type, 2016–2025
Table 14 : Europe Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapeutic Area, 2016–2025
Table 15 : Europe Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2025
Table 16 : Europe Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Country, 2016–2025
Table 17 : Asia Pacific Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapy Type, 2016–2025
Table 18 : Asia Pacific Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapeutic Area, 2016–2025
Table 19 : Asia Pacific Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2025
Table 20 : Asia Pacific Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Country, 2016–2025
Table 21 : Middle East & Africa Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapy Type, 2016–2025
Table 22 : Middle East & Africa Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapeutic Area, 2016–2025
Table 23 : Middle East & Africa Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2025
Table 24 : Middle East & Africa Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Country, 2016–2025